Why the DroneShield (ASX:DRO), BrainChip (ASX:BRN) and Recce (ASX:RCE) share prices are rising today

The share prices of these 3 ASX growth shares have all jumped today off the back of recent announcements. All are innovators in their fields.

| More on:
Red paper plane zooming ahead of an army of white paper plane competition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Today has been very strong for a range of ASX sectors after yesterday's market fall. We've seen the share prices of a number of innovative ASX growth companies rise today, including the 3 listed below.

DroneShield Ltd (ASX: DRO)

The Droneshield share price is up by 23.33% at time of writing.

The company provides non-ballistic detect and disrupt technology for defending against drones. It recently announced it had obtained funding from the US Department of Defence (DoD) for enhancements to its DroneShieldComplete Command-and-Control (C2) system. Previously, the company had made several announcements. First, relating to sales to 2 European nations, and second, to a successful deployment in a mid-sized European airport. This has also had an impact on the company's share price.

At the conclusion of the project to enhance the DroneShieldComplete C2, the company anticipates selling additional products to the US DoD. DroneShield CEO Oleg Vornik said the project underscored the company's leadership not only as a product/sensor manufacturer, but also as an integrator of fixed site and mobile counter unmanned aircraft systems.

Recce Pharmaceuticals Ltd (ASX: RCE)

Recce (pronounced Recky) is a medical research company developing a new range of synthetic antibiotics. Unlike current approaches, Recce's products kill bacteria instead of inhibiting growth, enabling multiple use without a reduction in potency. 

Today the company announced it has selected South Australia's CMAX Clinical Research as its independent trial facility. The laboratory will conduct a phase I clinical study of Recce's lead compound RECCE 327.

This is a controlled ascending dose study of 48 healthy adult subjects, resulting in an evaluation of the safety and tolerability of the product after intravenous use. In response to the news, the Recce share price has risen by 3.14% at the time of writing. 

Brainchip Holdings Ltd (ASX: BRN)

The BrainChip share price is up by 3.33% at the time of writing, and has risen by 73.33% over the past 5 days.

BrainChip is an artificial intelligence (AI) company that has recently completed construction of the wafer of its newest product, a neuromorphic chip designed to mimic the human brain and sensory system.

The company has announced 2 proof of concept partnerships.

First, with Magik Eye Inc to combine AI with the Magik Eye's 3D sensing. This partnership will be targeting gesture recognition in a wide array of gaming and consumer products. Second, the Brainchip share price jumped 54% after the company announced a partnership with VORAGO Technologies to support a phase 1 project for NASA.

Motley Fool contributor Daryl Mather owns shares of Recce Pharmaceuticals Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »